Key result
Next-generation sequencing and molecular genetic testing have substantially advanced the early diagnosis and management of hypertrophic cardiomyopathy, though 50-60% of patients remain without a clear causative genetic variant.
Genetic testing using next-generation sequencing has substantially advanced the molecular diagnosis and early detection of hypertrophic cardiomyopathy among family members.
Hypertrophic cardiomyopathy (HCM) is an inherited myocardial disease with the presence of left ventricular hypertrophy (LVH). The disease is characterized by high locus, allelic and phenotypic heterogeneity, even among members of the same family. The list of confirmed and potentially relevant genes implicating the disease is constantly increasing, with novel genes frequently reported. Heterozygous alterations in the five main sarcomeric genes (MYBPC3, MYH7, TNNT2, TNNI3, and MYL2) are estimated to account for more than half of confirmed cases. The genetic discoveries of recent years have shed more light on the molecular pathogenic mechanisms of HCM, contributing to substantial advances in the diagnosis of the disease. Genetic testing applying next-generation sequencing (NGS) technologies and early diagnosis prior to the clinical manifestation of the disease among family members demonstrate an important improvement in the field.
No takes yet. Share an insight, caveat, or question.
Melas et al. (2022) conducted a review in Hypertrophic cardiomyopathy (HCM). Molecular diagnosis and genetic testing (NGS) was evaluated. Next-generation sequencing and molecular genetic testing have substantially advanced the early diagnosis and management of hypertrophic cardiomyopathy, though 50-60% of patients remain without a clear causative genetic variant.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: